Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT06361745 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Idiopathic Inflammatory Myopathies
Systemic Sclerosis
IgG4 Related Disease
Primary Sjögren Syndrome

Interventions

BIOLOGICAL: T cell injection targeting CD19 chimeric antigen receptor

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.